

*AS*

49. (New) The method of Claim 21, wherein the condition is selected from the group consisting of coronary heart disease, atherosclerosis, head injury, ischemic stroke, intracerebral hemorrhage, normal pressure hydrocephalus, HIV-associated dementia and HIV-associated peripheral neuropathy.

#### REMARKS

Claims 2-9, 17-24 and 35-54 are now pending in the application. The amendments to the claims contained herein are of equivalent scope as originally filed and thus, are not a narrowing amendment.

#### CONCLUSION

It is believed that the present application is in condition for allowance and such allowance is courteously solicited. Thus, prompt and favorable consideration of this amendment is respectfully requested. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (248) 641-1600.

Respectfully submitted,

Dated: June 27, 2008

By: Barbara Gibbs  
Barbara S. Gibbs, Ph.D.  
Reg. No. 44,708

HARNESS, DICKEY & PIERCE, P.L.C.  
P.O. Box 828  
Bloomfield Hills, Michigan 48303  
(248) 641-1600

**BEST AVAILABLE COPY**

## **ATTACHMENT FOR CLAIM AMENDMENTS**

The following is a marked up version of each amended claim in which underlines indicates insertions and brackets indicate deletions.

2. [The method of Claim 1] A method of preventing toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD to a cell comprising treating said cell with a compound, wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

3. [The method of Claim 1] A method of preventing toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD to a cell comprising treating said cell with a compound, wherein the compound [further] comprises naphthalenesulfonic acid covalently bonded to a phenyl or naphthyl group.

4. The method of Claim [2] 3, wherein the naphthalenesulfonic acid is covalently bonded to a phenyl or naphthyl group through a diazo or amide bond.

5. The method of Claim [1] 3, wherein the compound is selected from the group consisting of ponceau S, Evan's blue, suramin sodium, direct blue 15, calconcarboxylic acid, amaranth, trypan blue, congo red, benzopurpurin 4b, Chicago sky blue 6b, sulfonazo III and mixtures thereof.

6. [The method of Claim 1] A method of preventing toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD to a cell comprising treating said cell with a compound, wherein the compound [further] comprises a triphenylmethane core modified with at least one sulfate or carboxylate group.

7. The method of Claim [1] 6, wherein the compound further comprises a triphenylmethane core modified with at least one benzoic acid or benzenesulfonic acid substituent.

9. The method of Claim [1] 6, wherein the compounds are selected from the group consisting of aurintricarboxylic acid, aniline blue, methyl blue, light green SF yellowish, Coomassie brilliant blue G-250, Coomassie brilliant blue R-250, and mixtures thereof.

17. [The method of Claim 16] A method of treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD, comprising administering a composition comprising a pharmacologically effective amount of a compound, wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

18. [The method of Claim 16] A method of treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD, comprising administering a composition comprising a pharmacologically effective amount of a compound, wherein the compound [further] comprises naphthalenesulfonic acid covalently bonded to a phenyl or naphthyl group.

20. The method of Claim [16] 18, wherein the compound is selected from the group consisting of ponceau S, Evan's blue, suramin sulfate, direct blue 15, calconcarboxylic acid, amaranth, trypan blue, congo red, benzopurpurin 4b, Chicago sky blue 6b, sulfonazo III and mixtures thereof.

21. [The method of Claim 16] A method of treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD, comprising administering a composition comprising a

pharmacologically effective amount of a compound, wherein the compound [further] comprises a triphenylmethane core modified with at least one sulfate or carboxylate group.

22. The method of Claim [16] 21, wherein the compound further comprises a triphenylmethane core modified with at least one benzoic acid or benzenesulfonic acid substituent.

24. The method of Claim [16] 21, wherein the compounds are selected from the group consisting of aurintricarboxylic acid, aniline blue, methyl blue, light green SF yellowish, Coomassie brilliant blue G-250, Coomassie brilliant blue R-250, and mixtures thereof.

10  
9  
8  
7  
6  
5  
4  
3  
2  
1  
0